The health coverage program’s enrollment soared during the three years after March 2020 due to temporary policies adopted at the start of the COVID-19 pandemic.
Discontinuing expanded health-care funding will result in less prenatal care for uninsured patients, more health risks, higher costs to the health system, and moral distress for health-care providers.
On the basis of government appointment technicalities and religious freedom, Americans may lose free coverage for cancer and blood pressure screenings, HIV prevention medication and other essential services.
Trauma insurance provides a benefit for life-threatening medical conditions that seriously compromise the insured person’s current and future quality of life.
Evidence from Massachusetts suggests that a multistep process discourages enrollment. The findings could help policymakers stave off a sharp decline in coverage when COVID-19 policies change.
Rachel A. Davis, University of Colorado Anschutz Medical Campus
This rare procedure is offered by only a handful of centers in the US and around the world and should be used only when less invasive treatment options for OCD have been tried.
Pandemic-related policies made it easier for states to afford to cover more people and made that coverage more stable for millions of Americans who rely on the program for health care.
Judge Reed O'Connor ruled in a case that coverage for HIV prevention medicine PrEP violated the religious freedom of the plaintiffs. It is unclear whether the order will extend nationwide.
A pending bill in Colorado would disclose donor information to children and their parents and set limits on how many families can use a single individual’s egg or sperm.
Most states have taken advantage of the opportunity to expand access to Medicaid since 2014 through the Affordable Care Act. That’s helping reduce the number of uninsured people.
The Affordable Care Act has allowed many preventive health services, including cancer screenings and vaccines, to be free of charge. But legal challenges may lead to costly repercussions for patients.
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
Quintiles Professor of Pharmaceutical Development and Regulatory Innovation, Schaeffer Center for Health Policy and Economics, University of Southern California